Compare BORR & ALMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BORR | ALMR |
|---|---|---|
| Founded | 2016 | N/A |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Laboratory Analytical Instruments |
| Sector | Energy | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.5B |
| IPO Year | 2017 | 2026 |
| Metric | BORR | ALMR |
|---|---|---|
| Price | $3.88 | $24.59 |
| Analyst Decision | Hold | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $6.25 | N/A |
| AVG Volume (30 Days) | ★ 4.0M | 241.2K |
| Earning Date | 05-20-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.80 | N/A |
| Revenue Next Year | $21.67 | N/A |
| P/E Ratio | $20.64 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.86 | $21.58 |
| 52 Week High | $6.66 | $29.43 |
| Indicator | BORR | ALMR |
|---|---|---|
| Relative Strength Index (RSI) | 31.96 | 50.57 |
| Support Level | $3.85 | $23.88 |
| Resistance Level | $4.61 | $29.06 |
| Average True Range (ATR) | 0.17 | 2.01 |
| MACD | -0.00 | -0.27 |
| Stochastic Oscillator | 0.69 | 18.55 |
Borr Drilling Ltd is an offshore shallow-water drilling contractor providing services to the oil and gas industry. Its operations focus on the ownership, contracting, and operation of jack-up rigs in shallow-water areas, including the provision of related equipment and work crews to conduct oil and gas drilling and workover operations for exploration and production (E&P) customers. The company contracts its rigs on a dayrate basis to drill wells for integrated oil companies, state-owned national oil companies, and independent oil and gas companies. It operates in one reportable segment.
Alamar Biosciences Inc is a proteomics company engaged in protein detection and analysis. The company has developed its own NULISA (NUcleic Acid Linked Immuno-Sandwich Assay) technology as the foundation of its Precision Proteomics platform enabling the detection and quantification of protein biomarkers in a single sample with ultra-high sensitivity and high specificity, even from very small volumes of biofluid. The company operates in single segment and focuses on developing a good sensitive proteomic liquid biopsy platform and sells instruments, consumables, and services based on this platform to enable early detection of diseases. The products of the company includes NULISAseq Panels, NULISAqpcr Assays, and others.